NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

惡性間皮癌 - 競爭情形:2021年

Malignant Mesothelioma - Competitive Landscape in 2021

出版商 GlobalData 商品編碼 1009986
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
惡性間皮癌 - 競爭情形:2021年 Malignant Mesothelioma - Competitive Landscape in 2021
出版日期: 2021年05月31日內容資訊: 英文 48 Pages
簡介

惡性間皮癌,表達間皮素的細胞是藥物開發人員的主要關注點。 在開發平台有178藥物,84%的分子開發處於初期在階段。,Bayer和Eli Lilly等大型製藥公司主導這個適應症的研究開發。接受治療的人口增加,對品牌的生物學的療法喜好,促進今後6年的市場成長,不過,診斷的延遲和監視率低有限制市場成長的可能性。

本報告提供惡性間皮癌的治療藥的現在、未來的競爭情形相關的系統性資訊。

目錄

目錄

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 上市藥的評估

  • 上市藥概要
  • 上市藥的簡介

第5章 開發平台的評估

  • 開發平台概要
  • 開發平台的明細:各地區
  • 開發平台的明細:各分子類型,各標的
  • 醫藥品的審查指定
  • 相變的成功率
  • 核準的可能性

第6章 臨床試驗的評估

  • 臨床試驗概要:各階段
  • 概要:各地區
  • 治療領域預測
  • 主要贊助商
  • 登記分析
  • 實行可能性分析

第7章 商業性評估

  • 未來市場促進因素

第8章 社群媒體與數位行銷

  • 主要的Twitter、Chatter
  • 領導品牌的網站
  • 信任來源和引用來源

第9章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC042CL

In malignant mesothelioma, cells expressing mesothelin is a major focus of drug developers. There are 178 drugs in the pipeline with 84% molecules present in early stage development. Big Pharma dominates R&D in this indication, with Bayer and Eli Lilly leading the way. The rise in treatment receiving population and increasing preference for branded tbiologic herapies will drive the market's growth over the next six years, but delayed diagnosis and low surveillance rate are likely to limit market growth.

This reports provides a data-driven overview of the current and future competitive landscape in malignant mesothelioma therapeutics.

GlobalData's "Malignant Mesothelioma - Competitive Landscape in 2021" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Scope

Components of the report include -

  • Disease epidemiology
  • Marketed drugs assessment
  • Pipeline drugs assessment
  • Clinical trials assessment
  • Commercial assessment
  • Social media overview
  • Digital marketing overview

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global malignant mesothelioma market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global malignant mesothelioma market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

  • 1.1 Table of Contents
  • 1.2 Abbreviations
  • 1.3 Related Reports
  • 1.4 Upcoming Related Reports

2 Executive Summary

  • 2.1 Key Findings
  • 2.2 Key Events

3 Introduction

  • 3.1 Report Scope
  • 3.2 Disease Overview Epidemiology Overview
  • 3.3 Epidemiology

4 Marketed Drugs Assessment

  • 4.1 Marketed Drugs Overview
  • 4.2 Marketed Drug Profiles

5 Pipeline Assessment

  • 5.1 Pipeline Overview
  • 5.2 Pipeline Breakdown by Region
  • 5.3 Pipeline Breakdown by Molecule Type and Target
  • 5.4 Drug Review Designations
  • 5.5 Phase Transition Success Rates
  • 5.6 Likelihood of Approval

6 Clinical Trial Assessment

  • 6.1 Clinical Trials Overview by Phase
  • 6.2 Overview by Region
  • 6.4 Therapy Area Perspective
  • 6.4 Leading Sponsors
  • 6.5 Enrollment Analytics
  • 6.6 Feasibility Analysis

7 Commercial Assessment

  • 7.1 Upcoming Market Catalysts

8 Social Media and Digital Marketing

  • 8.1 Key Twitter Chatter
  • 8.2 Top Branded Websites
  • 8.3 Trust Flow and Citation Flow

9 Appendix

  • 9.1 Methodology
  • 9.2 About the Authors
  • 9.3 About GlobalData
  • 9.4 Contact Us
  • 9.5 Disclaimer